Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting

被引：0
|
作者：
Della Gravara, Luigi [1 ]
Battiloro, Ciro [2 ]
Avellino, Aniello [2 ]
Caputo, Francesca [3 ]
D'Aniello, Carmine [3 ]
Rocco, Danilo [2 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy
[2] AORN Colli Monaldi, Dept Pulm Oncol, I-80131 Naples, Italy
[3] AORN Colli Monaldi, Dept Med Oncol, I-80131 Naples, Italy
来源：
JOURNAL OF MOLECULAR PATHOLOGY | 2023年 / 4卷 / 02期
关键词：
NSCLC; EGFR; MET; osimertinib; liquid biopsy; NGS; cfDNA; ctDNA; CELL LUNG-CANCER; TREATMENT ALGORITHM; OSIMERTINIB; THERAPY; C797S; 1ST;
D O I：
10.3390/jmp4020009
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
According to the ESMO and ASCO clinical guidelines, the main role of liquid biopsy in EGFR+ advanced NSCLC patients is represented by T790M detection after erlotinib/gefitinib/afatinib progression. However, the general international expert consensus regards osimertinib as the preferred upfront treatment in this setting; therefore, this role has been scaled back in recent years. As of today, liquid biopsy has no ASCO or ESMO recommendation following first-line osimertinib; in the same vein, no targeted therapy has received ASCO or ESMO recommendation following post upfront Osimertinib progression. However, this standard could change in the near future. Therefore, adopting a clinical point of view, this paper aims to provide a comprehensive review on the previous, the current and the possible future role of liquid biopsy in the framework of the diagnostic-therapeutic algorithm of EGFR+ advanced NSCLC.
引用
收藏
页码：81 / 88
页数：8
相关论文
共 50 条
  • [31] A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR-TKI Resistance
    Wang, Wenxian
    Song, Zhengbo
    Zhang, Yiping
    Jin, Ying
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S233 - S233
  • [32] A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
    Lu, S.
    Zhang, Y.
    Zhang, G.
    Zhou, J.
    Cang, S.
    Cheng, Y.
    Wu, G.
    Cao, P.
    Lv, D.
    Jian, H.
    Chen, C.
    Jin, X.
    Tian, P.
    Wang, K.
    Jiang, G.
    Chen, G.
    Chen, Q.
    Zhao, H.
    Ding, C.
    Guo, R.
    Sun, G.
    Wang, B.
    Jiang, L.
    Liu, Z.
    Fang, J.
    Yang, J.
    Zhuang, W.
    Liu, Y.
    Zhang, J.
    Pan, Y.
    Chen, J.
    Yu, Q.
    Zhao, M.
    Cui, J.
    Li, D.
    Yi, T.
    Yu, Z.
    Yang, Y.
    Zhang, Y.
    Zhi, X.
    Huang, Y.
    Wu, R.
    Chen, L.
    Zang, A.
    Cao, L.
    Li, Q.
    Li, X.
    Song, Y.
    Wang, D.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S469 - S469
  • [33] Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
    Papadimitrakopoulou, V. A.
    Wu, Y-L.
    Han, J-Y.
    Ahn, M-J.
    Ramalingam, S. S.
    John, T.
    Okamoto, I.
    Yang, J. C-H.
    Bulusu, K. C.
    Laus, G.
    Collins, B.
    Barrett, J. C.
    Chmielecki, J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 741 - 741
  • [34] Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC
    Leonetti, A.
    Bola, S.
    Minari, R.
    Scarlattei, M.
    Buti, S.
    Bordi, P.
    Baldari, G.
    Gnetti, L.
    Sammartano, A.
    Migliari, S.
    Cosenza, A.
    Ferri, L.
    Bonatti, F.
    Mastrodomenico, L.
    Ruffini, L.
    Tiseo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S610 - S610
  • [35] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
    Zhao, Sha
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    Shi, Jinpeng
    He, Yayi
    Li, Jiayu
    Zhou, Fei
    Gao, Guanghui
    Li, Wei
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 128 : 33 - 39
  • [36] Association of plasma EGFR T790M ctDNA status with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
    Zheng, Di
    Ye, Xin
    Zhang, Meizhuo
    Sun, Yun
    Wang, Jiying
    Ni, Jian
    Zhang, Haiping
    Zhang, Ling
    Luo, Jie
    Zhang, Jie
    Tang, Liang
    Su, Bo
    Chen, Gang
    Zhu, Guanshan
    Gu, Yi
    Xu, Jianfang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib Evaluating for a T790M Mutation With Limited Tissue
    Wynja, Emily
    Hove, Jenna
    Powell, Steven F.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 499 - 500
  • [38] ASTRIS a RWT with Osimertinib in NSCLC EGFR T790M Mutated: Disease Characteristics from Patients Included in Argentina
    Biolchi, M.
    Recondo, G.
    Casalnuovo, M.
    Tsou, F.
    Diaz Perez, I.
    Reinhold, F.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S169 - S169
  • [39] Amplification of EGFR T790M causes resistance to the irreversible EGFR inhibitor PF00299804
    Ercan, Dalia
    Zejnullahu, Kreshnik
    Xiao, Yun
    Capelletti, Marzia
    Rogers, Andrew
    Lee, Charles
    Christensen, James
    Janne, Pasi
    CANCER RESEARCH, 2009, 69
  • [40] Risk Factors for Developing T790M Mutation in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Ouyang, W.
    Xie, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E526 - E526
12345